Compare BABA & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BABA | AMGN |
|---|---|---|
| Founded | 1999 | 1980 |
| Country | Hong Kong | United States |
| Employees | 128197 | 31500 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.4B | 190.4B |
| IPO Year | N/A | 2002 |
| Metric | BABA | AMGN |
|---|---|---|
| Price | $94.83 | $355.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 19 |
| Target Price | $185.15 | ★ $351.05 |
| AVG Volume (30 Days) | ★ 10.1M | 2.9M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | 0.81% | ★ 2.98% |
| EPS Growth | N/A | ★ 88.23 |
| EPS | N/A | ★ 3.34 |
| Revenue | N/A | ★ $25,424,000,000.00 |
| Revenue This Year | $5.05 | $5.00 |
| Revenue Next Year | $10.83 | $2.45 |
| P/E Ratio | ★ $21.20 | $105.51 |
| Revenue Growth | N/A | ★ 8.83 |
| 52 Week Low | $94.71 | $269.77 |
| 52 Week High | $192.67 | $391.29 |
| Indicator | BABA | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 17.01 | 60.70 |
| Support Level | N/A | $334.72 |
| Resistance Level | $139.19 | $357.01 |
| Average True Range (ATR) | 2.68 | 8.88 |
| MACD | -1.71 | 1.00 |
| Stochastic Oscillator | 10.45 | 79.77 |
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China retail e-commerce platform is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China wholesale e-commerce, international retail and wholesale e-commerce, local consumer services, travel services, cloud computing, digital media and entertainment, Cainiao logistics services, and other businesses.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.